BACKGROUND: Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may be associated with response to therapy and survival in non-small-cell lung cancer (NSCLC). As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. METHODS:Serum CYFRA levels were measured at baseline and after the first cycle of treatment using an electrochemoluminescent assay. Paired specimens were available from 88 patients. The logarithms of the initial concentration and of the difference in concentrations were analyzed for association with overall survival (OS) and failure-free survival (FFS). RESULTS:Lower baseline CYFRA levels were associated with both longer OS and FFS (p < 0.0001 and p = 0.0003). In addition, larger reductions in CYFRA levels correlated with longer OS and FFS (p = 0.0255 and p = 0.0068). CONCLUSION: CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined.
RCT Entities:
BACKGROUND:Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may be associated with response to therapy and survival in non-small-cell lung cancer (NSCLC). As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. METHODS: Serum CYFRA levels were measured at baseline and after the first cycle of treatment using an electrochemoluminescent assay. Paired specimens were available from 88 patients. The logarithms of the initial concentration and of the difference in concentrations were analyzed for association with overall survival (OS) and failure-free survival (FFS). RESULTS: Lower baseline CYFRA levels were associated with both longer OS and FFS (p < 0.0001 and p = 0.0003). In addition, larger reductions in CYFRA levels correlated with longer OS and FFS (p = 0.0255 and p = 0.0068). CONCLUSION: CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined.
Authors: Susana Cedrés; Isaac Nuñez; Marina Longo; Pablo Martinez; Eva Checa; Davis Torrejón; Enriqueta Felip Journal: Clin Lung Cancer Date: 2011-04-24 Impact factor: 4.785
Authors: Robin T Vollmer; Ramaswamy Govindan; Stephen L Graziano; Gary Gamble; Jennifer Garst; Michael J Kelley; Robert H Christenson Journal: Clin Cancer Res Date: 2003-05 Impact factor: 12.531
Authors: Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: G Hillas; C Moschos; K Dimakou; F Vlastos; S Avgeropoulou; I Christakopoulou; A Rasidakis; P Bakakos Journal: Scand J Clin Lab Invest Date: 2008 Impact factor: 1.713
Authors: Michael Haas; Christoph Kern; Stephan Kruger; Marlies Michl; Dominik P Modest; Clemens Giessen; Christoph Schulz; Jobst C von Einem; Steffen Ormanns; Rüdiger P Laubender; Stefan Holdenrieder; Volker Heinemann; Stefan Boeck Journal: Tumour Biol Date: 2014-12-04
Authors: Daniel Ajona; Cristina Razquin; Maria Dolores Pastor; Maria Jose Pajares; Javier Garcia; Felipe Cardenal; Michael Fleischhacker; Maria Dolores Lozano; Javier J Zulueta; Bernd Schmidt; Ernest Nadal; Luis Paz-Ares; Luis M Montuenga; Ruben Pio Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240
Authors: S Boeck; C Wittwer; V Heinemann; M Haas; C Kern; P Stieber; D Nagel; S Holdenrieder Journal: Br J Cancer Date: 2013-04-11 Impact factor: 7.640